BRPI0418765B8 - composto da fórmula (i) e composição farmacêutica - Google Patents

composto da fórmula (i) e composição farmacêutica

Info

Publication number
BRPI0418765B8
BRPI0418765B8 BRPI0418765A BRPI0418765A BRPI0418765B8 BR PI0418765 B8 BRPI0418765 B8 BR PI0418765B8 BR PI0418765 A BRPI0418765 A BR PI0418765A BR PI0418765 A BRPI0418765 A BR PI0418765A BR PI0418765 B8 BRPI0418765 B8 BR PI0418765B8
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
inhibiting
tgf
formula
Prior art date
Application number
BRPI0418765A
Other languages
English (en)
Inventor
Kim Dae-Kee
Kim Hun-Taek
Cho Il-Sang
Hun Choi Joon
Park Myoung-Soon
Jae An Young
Bang Yung-Jue
Original Assignee
Ewha Univ Collaboration Foundation
Sk Chemicals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ewha Univ Collaboration Foundation, Sk Chemicals Co Ltd filed Critical Ewha Univ Collaboration Foundation
Publication of BRPI0418765A publication Critical patent/BRPI0418765A/pt
Publication of BRPI0418765B1 publication Critical patent/BRPI0418765B1/pt
Publication of BRPI0418765B8 publication Critical patent/BRPI0418765B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)

Abstract

composto, composição farmacêutica, método de inibir o tgf-b, método de reduzir o acúmulo de excesso de matriz extracelular, método de inibir metástase de células tumorais, método de tratar carcinomas, método de tratar uma doença, pró-droga, método de inibir trombose. esta invenção refere-se a imidazóis 2-piridil substituídos que são inibidores de transformação de crescimento fator-b(tgf-b)receptor tipo i (alk5) e/ou o receptor ativina tipo i (alk4), através de métodos de seu preparo e seu uso na medicina, especificamente no tratamento e prevenção de um estágio de doença rnediado por esses receptores.
BRPI0418765A 2004-04-21 2004-11-09 composto da fórmula (i) e composição farmacêutica BRPI0418765B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2004-0027591 2004-04-21
KR1020040027591A KR100749566B1 (ko) 2004-04-21 2004-04-21 Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체
PCT/KR2004/002891 WO2005103028A1 (en) 2004-04-21 2004-11-09 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors

Publications (3)

Publication Number Publication Date
BRPI0418765A BRPI0418765A (pt) 2007-10-09
BRPI0418765B1 BRPI0418765B1 (pt) 2019-06-04
BRPI0418765B8 true BRPI0418765B8 (pt) 2021-05-25

Family

ID=35196912

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0418765A BRPI0418765B8 (pt) 2004-04-21 2004-11-09 composto da fórmula (i) e composição farmacêutica

Country Status (14)

Country Link
US (1) US7407958B2 (pt)
EP (1) EP1620426A1 (pt)
JP (1) JP4678540B2 (pt)
KR (1) KR100749566B1 (pt)
CN (1) CN1972921B (pt)
AU (1) AU2004318777B2 (pt)
BR (1) BRPI0418765B8 (pt)
CA (1) CA2564442C (pt)
IL (1) IL178757A (pt)
MX (1) MXPA06012096A (pt)
NO (1) NO20064771L (pt)
RU (1) RU2348626C2 (pt)
WO (1) WO2005103028A1 (pt)
ZA (1) ZA200609626B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8420685B2 (en) * 2004-04-21 2013-04-16 Sk Chemicals Co., Ltd. 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors
US20080319012A1 (en) * 2004-04-21 2008-12-25 In2Gen Co., Ltd. 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors
US8410146B2 (en) * 2004-04-21 2013-04-02 Sk Chemicals Co., Ltd. 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors
CN101163502A (zh) 2005-02-08 2008-04-16 根茨美公司 针对TGFβ的抗体
BRPI0908906A2 (pt) * 2008-03-21 2019-09-24 Novartis Ag compostos heterocíclicos e usos dos mesmos
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
EP2299812B1 (en) * 2008-05-27 2017-07-12 Yale University Targeting tgf-beta as a therapy for alzheimer's disease
CN102083439A (zh) * 2008-05-30 2011-06-01 萨马保健系统有限责任公司 使用TGF-β受体抑制剂或活化素样激酶(ALK)5抑制剂A-83-01和SB-431542治疗眼病与伤口愈合症状的方法
US8513222B2 (en) 2010-06-29 2013-08-20 EWHA University—Industry Collaboration Foundation Methods of treating fibrosis, cancer and vascular injuries
US8080568B1 (en) * 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
USRE47141E1 (en) 2010-06-29 2018-11-27 EWHA University—Industry Collaboration Foundation Methods of treating fibrosis, cancer and vascular injuries
US9782452B2 (en) 2011-11-22 2017-10-10 Cornell University Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling
RU2475243C1 (ru) * 2012-02-16 2013-02-20 Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) Средство, обладающее антигипертензивной активностью
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
KR102434226B1 (ko) * 2016-06-30 2022-08-19 한미약품 주식회사 Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도
EP3515446B1 (en) 2016-09-19 2023-12-20 Novartis AG Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
US11266653B2 (en) 2017-05-02 2022-03-08 Novartis Ag Combination therapy
CN110066277B (zh) * 2018-01-24 2021-07-23 上海璎黎药业有限公司 芳香杂环取代烯烃化合物、其制备方法、药物组合物和应用
ES3025633T3 (en) 2019-05-13 2025-06-09 Novartis Ag New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
EP4087657A1 (en) 2020-01-08 2022-11-16 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
CN112266378B (zh) * 2020-11-09 2021-10-12 延边大学 含吲唑结构的咪唑类衍生物及其制备方法和应用
US12240830B2 (en) * 2021-08-13 2025-03-04 Bisichem Co., Ltd. Fused ring heteroaryl compounds and use thereof
CN115747214B (zh) * 2022-07-12 2025-11-18 安徽理工大学 Mlph基因在制备治疗尘肺病药物中的应用
EP4727586A1 (en) 2023-06-13 2026-04-22 Synthis Therapeutics, Inc. Anti-cd5 antibodies and their uses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656644A (en) * 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
DE69532245T2 (de) * 1994-09-26 2004-09-16 Shionogi & Co., Ltd. Imidazolderivat
CA2297176A1 (en) * 1997-04-24 1998-10-29 Ortho-Mcneil Pharmaceutical, Inc. Substituted imidazoles useful in the treatment of inflammatory diseases
JP2002541253A (ja) * 1999-04-09 2002-12-03 スミスクライン・ビーチャム・コーポレイション トリアリールイミダゾール
CO5271680A1 (es) * 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
GB0007405D0 (en) * 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
EP1391452A4 (en) 2001-05-25 2005-10-26 Mochida Pharm Co Ltd 4-HYDROXPIPERIDIN DERIVATIVE ANALGETIC EFFECT
JP2003040888A (ja) * 2001-07-30 2003-02-13 Sankyo Co Ltd イミダゾール誘導体
GB0218079D0 (en) * 2002-08-03 2002-09-11 Boatman Peter J A pipe and pipe assembly
KR20050057392A (ko) * 2002-09-18 2005-06-16 화이자 프로덕츠 인크. 전환성장인자(ｔｇｆ) 억제제로서의 신규한 이미다졸 화합물
US7250434B2 (en) * 2003-12-22 2007-07-31 Janssen Pharmaceutica N.V. CCK-1 receptor modulators

Also Published As

Publication number Publication date
US7407958B2 (en) 2008-08-05
MXPA06012096A (es) 2007-11-20
WO2005103028A1 (en) 2005-11-03
AU2004318777A1 (en) 2005-11-03
CN1972921A (zh) 2007-05-30
AU2004318777B2 (en) 2008-10-16
CN1972921B (zh) 2012-01-04
RU2006140989A (ru) 2008-05-27
BRPI0418765A (pt) 2007-10-09
KR20050102752A (ko) 2005-10-27
NO20064771L (no) 2007-01-19
BRPI0418765B1 (pt) 2019-06-04
JP2007533734A (ja) 2007-11-22
ZA200609626B (en) 2008-08-27
IL178757A (en) 2011-08-31
JP4678540B2 (ja) 2011-04-27
CA2564442A1 (en) 2005-11-03
RU2348626C2 (ru) 2009-03-10
CA2564442C (en) 2011-06-14
US20050261299A1 (en) 2005-11-24
IL178757A0 (en) 2007-02-11
KR100749566B1 (ko) 2007-08-16
EP1620426A1 (en) 2006-02-01

Similar Documents

Publication Publication Date Title
BRPI0418765A (pt) composto, composição farmacêutica, método de inibir o tgf-b, método de reduzir o acúmulo de excesso de matriz extracelular, método de inibir metástese de células tumorais, método de tratar carcinomas, método de tratar uma doença pró-droga, método de inibir trombose
CY1123625T1 (el) Συνθεσεις και μεθοδοι για θεραπεια διαταραχων χρησης αλκοολης, πονου και αλλων ασθενειων
CL2021000387A1 (es) Compuestos de anillo fusionado
NO20084374L (no) Imidazoltiazolforbindelser for behandling av sykdom
BRPI0805826A2 (pt) compostos espiro-substituìdos como inibidores de angiogênese, método de produção de um composto, composição farmacêutica e métodos de tratamento
CO6620028A2 (es) Imidazoles 2-piridil sustituidos como inhibidores terapéuticos de alk5 y/o alk 4
EA201170590A1 (ru) Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения
TW200714604A (en) Substituted heterocycles and the uses thereof
JOP20190151B1 (ar) مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان
SV2009003290A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
ECSP099634A (es) Derivados de piridazinona útiles como inhibidores de glucano sintasa
NO20093009L (no) Kondensert ring heterocykel kinase modulatorer
EA201100311A1 (ru) Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
DOP2011000074A (es) Compuestos y composiciones como inhibidores de proteina cinasa
NO20092470L (no) Substituerte diazepanforbindelser som orexinreseptorantagonister
EA200970085A1 (ru) Замещённые n-фенилметил-5-оксопролин-2-амиды в качестве антагонистов р2х7-рецептора и способы их применения
ATE469895T1 (de) Cgrp-rezeptorantagonisten
MX2009004699A (es) Compuestos de piridinona.
MX2009009843A (es) Compuestos espiro sustituidos como inhibidores de la angiogenesis.
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
NO20090608L (no) Tyrosinkinaseinhibitorer
EA201001371A1 (ru) Конденсированные пиримидиноновые соединения как модуляторы trpv3
NI201100166A (es) Derivados de benzofuranilo utilizados como inhibidores de glucoquinasa
UA107783C2 (en) Isoindoline compounds for use in treating cancer
NO20084396L (no) Kombinasjonsterapi

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2260 DE 29/04/2014.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: EWHA UNIVERSITY COLLABORATION FOUNDATION (KR) ; SK

B25A Requested transfer of rights approved

Owner name: EWHA UNIVERSITY COLLABORATION FOUNDATION (KR)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/06/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/06/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/11/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2800 DE 03-09-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.